Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prior Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7,054 result(s) found for: Prior Placebo. Displaying page 5 of 353.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-000697-11 Sponsor Protocol Number: SPIRIT-HF Start Date*: 2018-08-13
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolacto...
    Medical condition: Heart Failure (i.e. Heart Failure with mid-range/ moderately reduced ejection fraction (LVEF 40- 49 %) or with preserved ejection fraction (LVEF ≥ 50 %) with evidence of impaired left ventricular f...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted) AT (Prematurely Ended) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005012-42 Sponsor Protocol Number: 747-302 Start Date*: 2016-01-05
    Sponsor Name:Intercept Pharmaceuticals Inc.
    Full Title: A Phase 4, Double Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis. The COBALT S...
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Prematurely Ended) AT (Prematurely Ended) BE (Completed) DK (Prematurely Ended) FI (Prematurely Ended) GB (GB - no longer in EU/EEA) EE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing) DE (Completed) BG (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001178-31 Sponsor Protocol Number: YO42137 Start Date*: 2020-08-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WH...
    Medical condition: Esophageal squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10055476 Esophageal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) HU (Completed) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003510-16 Sponsor Protocol Number: EFC15156 Start Date*: 2018-05-07
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabet...
    Medical condition: Cardiovascular diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) ES (Prematurely Ended) LV (Completed) LT (Completed) GB (Completed) BE (Completed) DK (Prematurely Ended) FR (Completed) AT (Completed) CZ (Prematurely Ended) DE (Completed) SK (Completed) HU (Completed) FI (Completed) PT (Completed) GR (Completed) PL (Completed) IE (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-004216-31 Sponsor Protocol Number: CIGE025E2201 Start Date*: 2012-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multi-centre, randomized, double blind, placebo-controlled study to determine the mode of action of omalizumab in patients with chronic idiopathic urticaria (CIU) who remain symptomatic...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003627-38 Sponsor Protocol Number: H3M116477 Start Date*: 2013-01-30
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) CZ (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004313-15 Sponsor Protocol Number: NI-0401-01 Start Date*: 2006-07-14
    Sponsor Name:NovImmune S.A.
    Full Title: A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-Escalation Study of NI-0401 in Patients with Moderate to Severe Active Crohn´s Disease
    Medical condition: Moderate to Severe Active Crohn´s Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000539-27 Sponsor Protocol Number: CLAF237A2307 Start Date*: 2004-09-08
    Sponsor Name:Novartis Sverige AB
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg qd to Placebo in Drug-Naïve Patients with Type 2 Diabetes and Mild Hyperg...
    Medical condition: Type 2 Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015066-61 Sponsor Protocol Number: ACT10776 Start Date*: 2009-12-11
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Efficacy and safety of SAR407899A in patients with painful diabetic neuropathy. A 28-day, randomized, double-blind, placebo-controlled, parallel-group study.
    Medical condition: Diabetic peripheral neuropathic pain
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-018501-10 Sponsor Protocol Number: BAY43-9006/12444 Start Date*: 2011-03-23
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Phase III Randomized, Double blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negativ...
    Medical condition: Locally advanced or metastatic HER2-negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10004244 Benign breast neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) AT (Completed) CZ (Completed) IE (Completed) ES (Completed) HU (Completed) IT (Completed) GR (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000671-25 Sponsor Protocol Number: 1242-001 Start Date*: 2016-09-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in S...
    Medical condition: Treatment of chronic heart failure with reduced ejection fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) DK (Completed) NL (Completed) FI (Completed) PL (Completed) BE (Completed) GR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002693-66 Sponsor Protocol Number: 0822-018 Start Date*: 2007-11-13
    Sponsor Name:MERCK SHARP & DOHME CORP.
    Full Title: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D an...
    Medical condition: Postmenopausal Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Elderly Gender: Female
    Trial protocol: LT (Completed) DK (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) DE (Completed) FR (Prematurely Ended) BE (Prematurely Ended) LV (Completed) EE (Completed) IT (Completed) ES (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000744-34 Sponsor Protocol Number: 204939 Start Date*: 2019-06-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, observer-blind, placebo controlled, multicenter clinical trial to assess Herpes Zoster recurrence and the reactogenicity, safety and immunogenicity of GSK Biologicals’ Herp...
    Medical condition: Healthy volunteers (Prevention of Herpes Zoster)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-004409-24 Sponsor Protocol Number: AK130940 Start Date*: 2005-06-08
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150m...
    Medical condition: Major Depressive Disorder (MDD)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001246-13 Sponsor Protocol Number: TV3/001/06 Start Date*: 2007-01-22
    Sponsor Name:Oxford BioMedica UK Ltd.
    Full Title: Estudio internacional, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos, para investigar si Trovax, añadido al tratamiento estándar de primera linea, prolonga la supervivenci...
    Medical condition: Locally advanced or metastatic renal clear cell adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000942-32 Sponsor Protocol Number: IZD334-002 Start Date*: 2020-07-16
    Sponsor Name:Inflazome Ireland Ltd.
    Full Title: A 12-week, multi-center, double-blinded, parallel-group, randomized, placebo-controlled phase IIb study to evaluate the safety, tolerability and efficacy of IZD334 to reduce CRP in cardiovascular h...
    Medical condition: Patients with stable coronary artery disease and high cardiovascular risk
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005732-29 Sponsor Protocol Number: MOM-M281-011 Start Date*: 2021-11-19
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generali...
    Medical condition: Myasthenia gravis (MG).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004131-24 Sponsor Protocol Number: 67896062CTP3001 Start Date*: 2020-05-29
    Sponsor Name:ACTELION Pharmaceuticals Ltd.
    Full Title: A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in ino...
    Medical condition: Chronic thromboembolic pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) ES (Prematurely Ended) AT (Completed) SK (Completed) LT (Completed) FR (Completed) IT (Prematurely Ended) PT (Prematurely Ended) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003609-24 Sponsor Protocol Number: CLOU064D12201 Start Date*: 2019-10-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject- and investigator-blinded, placebo controlled study to assess the efficacy and safety of LOU064 in patients with inadequately controlled asthma
    Medical condition: Inadequately controlled asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000546-31 Sponsor Protocol Number: A3051104 Start Date*: 2008-07-16
    Sponsor Name:Pfizer Ltd, Ramsgate Road,Sandwich,Kent CT13 9NJ
    Full Title: A RANDOMIZED, MULTICENTRE, DOUBLE BLIND, PLACEBO CONTROLLED STUDY EVALUATING THE EFFICACY OF VARENICLINE IN CESSATION OF ORAL TOBACCO USE
    Medical condition: Cessation of oral smokeless tobacco use in current non-smokers.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053325 Smoking cessation therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 01:01:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA